Ray Dalio Intellia Therapeutics, Inc. Transaction History

Bridgewater Associates, LP

  • $17.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
BUY
$33.21 - $62.69 $311,742 - $588,471
9,387 New
9,387 $327,000
Q2 2022

Aug 11, 2022
SELL
$38.49 - $76.21 $188,870 - $373,962
-4,907 Closed
0 $0
Q1 2022

May 13, 2022
BUY
$58.27 - $118.99 $285,930 - $583,883
4,907 New
4,907 $357,000

Others Institutions Holding NTLA

# of Institutions
314
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email